NEW YORK--(BUSINESS WIRE)--
- Institute collaborates with leading influencers in life sciences to solve industry challenges and provide fresh perspectives
- Initial partnerships with Castleman Disease Collaborative Network and Friends of Cancer Research deliver insights that improve treatment options and reduce the need for control arm patients
Medidata (MDSO) announced today that the Medidata Institute is working with industry partners to deliver insights that redefine how technology, data and AI can improve lives and inspire the next generation of medical treatments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190603005385/en/
Medidata's decades of technical and industry experience uniquely position the company to work with and unite leaders across the life sciences via the Medidata Institute - including researchers, regulatory bodies, patient advocacy groups and other organizations.
“The Medidata Institute was established in support of our company’s mission of powering smarter treatments and healthier people,” said Glen de Vries, co-founder and president, Medidata. “This forum challenges the industry to think in new ways about how technology can fundamentally improve the way we conduct research and deliver treatments to patients in need.”
To date, Medidata has partnered with Friends of Cancer Research (Friends) and The Castleman Disease Collaborative Network (CDCN) -- two organizations focused on bringing better treatments to patients through collaboration.
Medidata is part of a working group led by Friends comprised of representatives from the FDA, pharmaceutical companies, academia and patient advocacy. The group seeks to address the challenge of randomized control trials and explores the power of external controls, such as synthetic control arms (SCA).
By leveraging advanced analytics and patient-level data from multiple historical clinical trials, Medidata and Friends demonstrated in a non-small cell lung cancer case study that SCAs can mimic the results of a traditional randomized control. Specifically, the overall survival (OS) of the target randomized control was replicated by the SCA. These findings hold promise in identifying ways to reduce the number of patients needed for a randomized control arm. More information can be found here.
“The vast amount of data available in the life sciences today offers an opportunity to transform the clinical trial process,” said Mark Stewart, vice president, science policy, Friends of Cancer Research. “Partnering with the Medidata Institute to make these data actionable is a game-changing effort that will enhance the clinical trial experience for patients and propel next gen therapies.”
Medidata has also partnered with CDCN to advance personalized medicine for patients with this life-threatening, rare disorder. Using a machine learning-based solution, researchers discovered new patient subgroups within a population of Castleman Disease patients and uncovered novel insights into treatment response and potential new drug targets for these patients.
To learn more about the Medidata Institute and the insights being uncovered, visit here.
About Friends of Cancer Research
Friends of Cancer Research (Friends) drives collaboration among partners from every healthcare sector to power advances in science, policy, and regulation that speed lifesaving treatments to patients. For more information, please visit www.focr.org.
About the Medidata Institute
Building on more than 20 years experience in technology, data and analytics, Medidata launched the Medidata Institute to provide unique insights, inspire the next generation of treatments, and improve patient lives. The Medidata Institute works in partnership with life science companies, researchers, regulatory agencies, patient advocates and international organizations to solve challenges in treatment research, development, and delivery.
Medidata is leading the digital transformation of life science, with the world's most used platform for clinical development, commercial, and real-world data. Powered by artificial intelligence and delivered by top ranked industry experts, Medidata helps pharmaceutical, biotech, medical device companies, and academic researchers accelerate value, minimize risk and optimize outcomes. Medidata and its companies, Acorn AI and SHYFT, serve more than 1,200 customers and partners worldwide and empower more than 150,000 certified users every day to create hope for millions of patients. Discover the future of life science: www.medidata.com